About us

We aim to deliver on the promise of gene therapy for people with debilitating chronic diseases

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV)-vector-mediated systemic gene therapies.

We are dedicated to improving patient lives through innovative, one-time treatments We use our proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells to express a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream.

We are advancing a clinical program in Gaucher disease and early-stage efforts in various targets.